Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases
Tocilizumab appears to mitigate systemic inflammation and improve outcomes in children with refractory septic shock and elevated IL-6 levels. Further prospective studies are warranted to confirm these findings and establish treatment guidelines.
Authors
- Han‐Ping Wu (ORCID: https://orcid.org/0000-0002-0069-4183)
- En‐Pei Lee
- Shih‐Hsiang Chen (ORCID: https://orcid.org/0000-0003-2588-2735)
- Jainn‐Jim Lin (ORCID: https://orcid.org/0000-0001-5592-6343)
- Man‐Ru Hsiao
- Ya-Ting Su
- Shao‐Hsuan Hsia
- Oi‐Wa Chan
Institutions
- Chang Gung University (TW)
- University of Maryland Eastern Shore (US)
- Chang Gung Memorial Hospital (TW)
- Chiayi Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Cells
- Published
- 2025-03-16
- DOI
- https://doi.org/10.3390/cells14060441
- Citations
- 3
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Chang Gung Memorial Hospital